methyl 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinate | 847373-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinate
• 英文别名: 4-(4-bromo-2-chloro-phenylamino)-5,6-dichloro-nicotinic acid methyl ester；4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid methyl ester；methyl 4-(4-bromo-2-chloroanilino)-5,6-dichloropyridine-3-carboxylate
• CAS: 847373-09-5
• 化学式: C₁₃H₈BrCl₃N₂O₂
• 分子量: 410.482
• InChiKey: OVHUPKYGIWERSV-UHFFFAOYSA-N

物化性质

• 沸点：
  421.7±45.0 °C(Predicted)
• 密度：
  1.720±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinate 在 sodium hydroxide 、 sodium hydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

  摘要：

  The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.

  DOI：

  10.1021/jm050834y
• 作为产物：
  描述：

  4,6-二羟基烟酸乙酯 在 sodium hydroxide 、 N-氯代丁二酰亚胺 、 TEA 、 lithium hexamethyldisilazane 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 77.5h， 生成 methyl 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinate
  参考文献：
  名称：

  Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

  摘要：

  The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.

  DOI：

  10.1021/jm050834y

文献信息

• Heterocyclic inhibitors of MEK and methods of use thereof
  申请人：Wallace Eli

  公开号：US20050049419A1

  公开（公告）日：2005-03-03

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 , R 9 and R 10 , W and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

  本发明涉及具有式I的化合物及其药用可接受的盐和前药，其中R1、R2、R7、R8、R9和R10、W和Y如规范中所定义。这些化合物是MEK抑制剂，在哺乳动物中用于治疗高增殖性疾病，如癌症和炎症。还公开了在哺乳动物中使用这些化合物治疗高增殖性疾病的方法以及含有这些化合物的药物组合物。
• Method of treating inflammatory diseases
  申请人：Koch Kevin

  公开号：US20060030610A1

  公开（公告）日：2006-02-09

  Disclosed are methods of treating inflammatory diseases and disorders, such as arthritis and inflammatory bowel disease, in mammals.

  本发明涉及一种治疗哺乳动物的炎症性疾病和疾病的方法，例如关节炎和炎症性肠病的方法。
• Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK
  申请人：Wallace Eli

  公开号：US20060189668A1

  公开（公告）日：2006-08-24

  Disclosed are methods of inhibiting MEK activity, comprising administering to a mammal an effective amount of a compound of Formula I or IV or a solvate or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 7 , R 8 , R 9 , R 10 , W and Y are as defined in the specification. Also disclosed are methods of treating hyperproliferative diseases, such as cancer and inflammation, in mammals, said method comprising administering to a mammal an effective amount of a compound of Formula I or IV.

  本发明公开了一种抑制MEK活性的方法，包括向哺乳动物施用化合物I或IV的有效量，或其溶剂或药学上可接受的盐，其中R1、R2、R7、R8、R9、R10、W和Y如规范中所定义。本发明还公开了一种治疗哺乳动物的高增殖性疾病，如癌症和炎症的方法，该方法包括向哺乳动物施用化合物I或IV的有效量。
• Inhibitors of MEK
  申请人：Vernier Jean-Michel

  公开号：US20080255133A1

  公开（公告）日：2008-10-16

  This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

  本发明涉及N-(2-烷基氨基)芳基磺酰胺，其为MEK抑制剂，以及使用这些化合物治疗过度增生性疾病的方法，以及含有这些化合物的制药组合物。
• INHIBITORS OF MEK
  申请人：Koh Yung-hyo

  公开号：US20100331334A1

  公开（公告）日：2010-12-30

  This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

  这项发明涉及N-(2-烷基氨基)芳基磺酰胺，它们是MEK的抑制剂，使用这些化合物治疗增殖过度性疾病的方法，以及含有这些化合物的药物组合物。